Literature DB >> 22251432

Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.

Igor F Tsigelny1, Yuriy Sharikov, Wolfgang Wrasidlo, Tania Gonzalez, Paula A Desplats, Leslie Crews, Brian Spencer, Eliezer Masliah.   

Abstract

Parkinson's disease (PD) and dementia with Lewy bodies are common disorders of the aging population and characterized by the progressive accumulation of α-synuclein (α-syn) in the central nervous system. Aggregation of α-syn into oligomers with a ring-like appearance has been proposed to play a role in toxicity. However, the molecular mechanisms and the potential sequence of events involved in the formation of pore-like structures are unclear. We utilized computer modeling and cell-based studies to investigate the process of oligomerization of wild-type and A53T mutant α-syn in membranes. The studies suggest that α-syn penetrates the membrane rapidly, changing its conformation from α-helical towards a coiled structure. This penetration facilitates the incorporation of additional α-syn monomers in the complex, and the subsequent displacement of phospholipids and the formation of oligomers in the membrane. This process occurred more rapidly, and with a more favorable energy of interaction, for mutant A53T compared with wild-type α-syn. After 4 ns of simulation of the protein-membrane model, α-syn had penetrated through two-thirds of the membrane. By 9 ns, the penetration of the annular α-syn oligomers can result in the formation of pore-like structures that fully perforate the lipid bilayer. Experimental incubation of recombinant α-syn in synthetic membranes resulted in the formation of similar pore-like complexes. Moreover, mutant (A53T) α-syn had a greater tendency to accumulate in neuronal membrane fractions in cell cultures, resulting in greater neuronal permeability, as demonstrated with the calcein efflux assay. These studies provide a sequential molecular explanation for the process of α-syn oligomerization in the membrane, and support the role of formation of pore-like structures in the pathogenesis of the neurodegenerative process in PD.
© 2012 The Authors Journal compilation © 2012 FEBS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251432      PMCID: PMC3925782          DOI: 10.1111/j.1742-4658.2012.08489.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  61 in total

1.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

4.  Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method.

Authors:  M Cserzö; E Wallin; I Simon; G von Heijne; A Elofsson
Journal:  Protein Eng       Date:  1997-06

5.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.

Authors:  A Takeda; M Mallory; M Sundsmo; W Honer; L Hansen; E Masliah
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

6.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

8.  Constant pressure and temperature molecular dynamics simulation of a fully hydrated liquid crystal phase dipalmitoylphosphatidylcholine bilayer.

Authors:  K Tu; D J Tobias; M L Klein
Journal:  Biophys J       Date:  1995-12       Impact factor: 4.033

9.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.

Authors:  K Wakabayashi; K Matsumoto; K Takayama; M Yoshimoto; H Takahashi
Journal:  Neurosci Lett       Date:  1997-12-12       Impact factor: 3.046

10.  Mechanism of membrane interaction and disruption by α-synuclein.

Authors:  Nicholas P Reynolds; Alice Soragni; Michael Rabe; Dorinel Verdes; Ennio Liverani; Stephan Handschin; Roland Riek; Stefan Seeger
Journal:  J Am Chem Soc       Date:  2011-11-09       Impact factor: 15.419

View more
  63 in total

Review 1.  Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.

Authors:  Durga Dharmadana; Nicholas P Reynolds; Charlotte E Conn; Céline Valéry
Journal:  Interface Focus       Date:  2017-06-16       Impact factor: 3.906

2.  Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration.

Authors:  Edward F Griffin; Xiaohui Yan; Kim A Caldwell; Guy A Caldwell
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

3.  The cellular membrane as a mediator for small molecule interaction with membrane proteins.

Authors:  Christopher G Mayne; Mark J Arcario; Paween Mahinthichaichan; Javier L Baylon; Josh V Vermaas; Latifeh Navidpour; Po-Chao Wen; Sundarapandian Thangapandian; Emad Tajkhorshid
Journal:  Biochim Biophys Acta       Date:  2016-05-06

Review 4.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

Review 5.  Parkinson's disease: proteinopathy or lipidopathy?

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  NPJ Parkinsons Dis       Date:  2020-01-03

6.  Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

Authors:  Omar El-Agnaf; Cassia Overk; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Nishant Vaikath; Nour Majbour; Seung-Jae Lee; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2017-05-02       Impact factor: 5.996

Review 7.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

8.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

Review 9.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 10.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.